Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07591038 · ClinicalTrials.gov registry record
PET/CT Imaging in Carriers of TTR Mutations
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- 80
- Enrollment target
NCT07591038 is a clinical trial that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 80 participants.
The verdict
NCT07591038 has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E). Participants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET/CT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET/CT to make amyloidosis visible in the heart and body.
Interventions
- DIAGNOSTIC_TEST Iodine-124 Evuzamitide (I-124E)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07591038
The ClinicalTrials.gov registry entry for NCT07591038 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iodine-124 Evuzamitide (I-124E) is the first listed.
NCT07591038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07591038 about?
NCT07591038 is a clinical study titled "PET/CT Imaging in Carriers of TTR Mutations". The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E). Participants will undergo a screening that includes a medical history review and completion of quality-of-life ...
What is the current status of trial NCT07591038?
This trial is currently not yet recruiting. The enrollment target is 80 participants. The study started on 2026-08-01. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT07591038?
The interventions under investigation include: Iodine-124 Evuzamitide (I-124E) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07591038?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.